| GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS |
PKU GMPro MIX-IN® |
Nutricia Australia Pty Limited |
Phenylketonuria |
Mar 2022 |
Recommended |
| IXAZOMIB |
Ninlaro® |
Takeda Pharmaceuticals Australia Pty. Ltd. |
Multiple myeloma |
Mar 2022 |
Not Recommended |
| FREMANEZUMAB |
Ajovy® |
Teva Pharma Australia Pty Ltd |
Chronic migraine |
Mar 2022 |
Recommended |
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Second-line squamous cell oesophageal carcinoma |
Mar 2022 |
Recommended |
| ENFORTUMAB VEDOTIN |
Padcev® |
Astellas Pharma Australia Pty Ltd |
Urothelial cancer |
Mar 2022 |
Not Recommended |
| SOTORASIB |
Lumakras® |
Amgen Australia Pty Limited |
Non-small cell lung cancer |
Mar 2022 |
Not Recommended |
| SEMAGLUTIDE |
Wegovy® |
Novo Nordisk Pharmaceuticals Pty. Limited |
Obesity |
Mar 2022 |
Not Recommended |
| VERICIGUAT |
Verquvo® |
Bayer Australia Ltd |
Chronic heart failure |
Mar 2022 |
Not Recommended |
| ZANUBRUTINIB |
Brukinsa® |
BeiGene Aus Pty Ltd |
Waldenstrom macroglobulinemia |
Mar 2022 |
Recommended |
| SOMAPACITAN |
Sogroya® |
Novo Nordisk Pharmaceuticals Pty. Limited |
Adult growth hormone deficiency |
Mar 2022 |
Recommended |
| TRIGLYCERIDES, MEDIUM CHAIN |
K.Quik® |
Vitaflo Australia Pty Limited |
Ketogenic diet |
Mar 2022 |
Recommended |
| BECLOMETASONE WITH FORMOTEROL |
Fostair® |
Chiesi Australia Pty Ltd |
Chronic obstructive pulmonary disease |
Mar 2022 |
Recommended |
| BIMEKIZUMAB |
Bimzelx® |
UCB Australia Proprietary Limited |
Plaque psoriasis |
Mar 2022 |
Recommended |
| SELINEXOR |
Xpovio® |
Antengene (Aus) Pty. Ltd. |
Triple class refractory/penta-refractory multiple myeloma |
Mar 2022 |
Recommended |
| CABAZITAXEL |
Cabazitaxel Accord® |
Accord Healthcare Pty. Ltd. |
Prostate cancer |
Mar 2022 |
Recommended |
| CEMIPLIMAB |
Libtayo® |
sanofi-aventis Australia Pty Ltd |
Squamous cell carcinoma |
Mar 2022 |
Recommended |
| ABEMACICLIB |
Verzenio™ |
Eli Lilly Australia Pty Ltd |
Breast cancer |
Mar 2022 |
Not Recommended |
| DIROXIMEL FUMARATE |
Vumerity® |
Biogen Australia Pty Ltd |
Multiple sclerosis |
Mar 2022 |
Recommended |
| DULAGLUTIDE |
Trulicity® |
Eli Lilly Australia Pty Ltd |
Type 2 diabetes mellitus |
Mar 2022 |
Deferred |
| PALBOCICLIB |
Ibrance® |
Pfizer Australia Pty Ltd |
Breast cancer |
Mar 2022 |
Recommended |
| RISANKIZUMAB |
Skyrizi® |
AbbVie Pty Ltd |
Psoriatic arthritis |
Mar 2022 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Renal cell carcinoma |
Mar 2022 |
Recommended |
| RABEPRAZOLE |
Pariet® |
Janssen-Cilag Pty Ltd |
Complex gastro-oesophageal reflux disease; Scleroderma oesophagus; Gastro-oesophageal
reflux disease; Peptic ulcer. |
Mar 2022 |
Recommended |
| SEBELIPASE ALFA |
Kanuma® |
Alexion Pharmaceuticals Australasia Pty Ltd |
Infantile onset lysosomal acid lipase deficiency |
Mar 2022 |
Not Recommended |
| RANIBIZUMAB |
Susvimo® |
Roche Products Pty Ltd |
Neovascular (wet) age-related macular degeneration |
Mar 2022 |
Deferred |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Endometrial cancer |
Mar 2022 |
Recommended |
| PALIPERIDONE |
Invega Hafyera® |
Janssen-Cilag Pty Ltd |
Schizophrenia |
Mar 2022 |
Recommended |
| VENETOCLAX |
Venclexta® |
Abbvie Pty Ltd |
Chronic lymphocytic leukaemia or small lymphocytic lymphoma |
Mar 2022 |
Not Applicable |
| SOMATROGON |
Ngenla® |
Pfizer Australia Pty Ltd |
Paediatric growth hormone deficiency |
Mar 2022 |
Recommended |
| SELINEXOR |
Xpovio® |
Antengene (Aus) Pty. Ltd. |
Relapsed and/or refractory multiple myeloma |
Mar 2022 |
Not Recommended |
| DURVALUMAB |
Imfinzi® |
AstraZeneca Pty Ltd |
Unresectable Stage III non-small cell lung cancer |
Mar 2022 |
Recommended |
| FREMANEZUMAB |
Ajovy® |
Teva Pharma Australia Pty Ltd |
Chronic migraine |
Mar 2022 |
Recommended |
| DOSTARLIMAB |
Jemperli® |
GlaxoSmithKline Australia Pty Ltd |
Endometrial cancer |
Mar 2022 |
Not Recommended |
| GLATIRAMER |
Copaxone® |
Teva Pharma Australia Pty Ltd |
Multiple sclerosis |
Mar 2022 |
Recommended |
| INFLIXIMAB |
Remsima® SC |
Celltrion Healthcare Australia Pty Ltd |
Ankylosing spondylitis; Psoriatic arthritis; Chronic plaque psoriasis; Refractory
fistulising Crohn Disease. |
Mar 2022 |
Recommended |
| NIRAPARIB |
Zejula® |
GlaxoSmithKline Australia Pty Ltd |
High grade epithelial ovarian; fallopian tube; or primary peritoneal cancer |
Mar 2022 |
Recommended |
| BUROSUMAB |
Crysvita® |
Kyowa Kirin Australia Pty Ltd |
X-linked hypophosphataemia |
Mar 2022 |
Not Recommended |
| BEVACIZUMAB |
Bevaciptin® |
Cipla Australia Pty Ltd |
Cancers |
Mar 2022 |
Recommended |
| CARFILZOMIB |
Kyprolis® |
Amgen Australia Pty Limited |
Multiple myeloma |
Mar 2022 |
Recommended |
| APREMILAST |
Otezla® |
Amgen Australia Pty Limited |
Severe chronic plaque psoriasis |
Mar 2022 |
Recommended |
| CANNABIDIOL |
Epidyolex® |
Chiesi Australia Pty Ltd |
Lennox-Gastaut syndrome |
Mar 2022 |
Not Recommended |
| RISANKIZUMAB |
Skyrizi® |
AbbVie Pty Ltd |
Severe chronic plaque psoriasis |
Mar 2022 |
Recommended |
| OZANIMOD |
Zeposia® |
Celgene Pty Limited |
Ulcerative colitis |
Mar 2022 |
Recommended |
| PEGCETACOPLAN |
Empaveli™ |
Swedish Orphan Biovitrum Pty Ltd |
Paroxysmal nocturnal haemoglobinuria |
Mar 2022 |
Not Recommended |
| SECUKINUMAB |
Cosentyx® |
Novartis Pharmaceuticals Australia Pty Limited |
Non-radiographic axial spondyloarthritis; Severe active psoriatic arthritis; Severe
psoriatic arthritis; Ankylosing spondylitis; Active ankylosing spondylitis; Severe
chronic plaque psoriasis. |
Mar 2022 |
Recommended |
| ENZALUTAMIDE |
Xtandi® |
Astellas Pharma Australia Pty Ltd |
Prostate cancer |
Mar 2022 |
Recommended |
| ABIRATERONE AND METHYLPREDNISOLONE |
Yonsa®MPRED |
Sun Pharma ANZ Pty Ltd |
Prostate cancer |
Mar 2022 |
Not Recommended |
| BORTEZOMIB |
Bortezomib Ever Pharma® |
Interpharma Pty Ltd |
Multiple Myeloma |
Mar 2022 |
Recommended |
| DORZOLAMIDE WITH TIMOLOL |
VIzo-PF Dorzolatim® |
Aft Pharmaceuticals (Au) Pty Ltd |
Elevated intra-ocular pressure |
Mar 2022 |
Recommended |
| CICLOSPORIN |
Cequa® |
Sun Pharma ANZ Pty Ltd |
Chronic severe dry eye disease with keratitis |
Mar 2022 |
Recommended |
| DUPILUMAB |
Dupixent® |
sanofi-aventis Australia Pty Ltd |
Atopic dermatitis |
Mar 2022 |
Recommended |
| NUSINERSEN |
Spinraza® |
Biogen Australia Pty Ltd |
Spinal muscular atrophy |
Mar 2022 |
Recommended |
| METHYLPHENIDATE |
Ritalin® LA |
Novartis Pharmaceuticals Australia Pty Limited |
Attention deficit hyperactivity disorder |
Mar 2022 |
Recommended |
| GALCANEZUMAB |
Emgality® |
Eli Lilly Australia Pty Ltd |
Migraine |
Mar 2022 |
Recommended |
| GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS |
PKU GMPro ULTRA® |
Nutricia Australia Pty Limited |
Phenylketonuria |
Mar 2022 |
Recommended |
| SACITUZUMAB GOVITECAN |
Trodelvy® |
Gilead Sciences Pty Limited |
Breast cancer |
Mar 2022 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Resubmission to request a Section 100 (Efficient Funding of Chemotherapy Program)
Authority Required (STREAMLINED) listing for the first-line treatment of recurrent
or metastatic Squamous cell carcinoma of the head and neck (SCCHN). |
Mar 2022 |
Recommended |
| GILTERITINIB |
Xospata® |
Astellas Pharma Australia Pty Ltd |
Acute myeloid leukaemia |
Mar 2022 |
Recommended |
| TRIENTINE |
Cuprior® |
Orphalan |
Wilson disease |
Mar 2022 |
Not Recommended |
| DAPAGLIFLOZIN |
Forxiga® |
Astrazeneca Pty Ltd |
Chronic kidney disease |
Mar 2022 |
Recommended |
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Non-HER-2-positive gastric cancer, gastroesophageal junction cancer or oesophageal
adenocarcinoma |
Mar 2022 |
Recommended |
| AMIFAMPRIDINE |
Ruzurgi® |
The Trustee For Orspec Pharma Unit Trust |
Lambert-Eaton myasthenic syndrome |
Mar 2022 |
Recommended |
| MECASERMIN |
Increlex® |
Ipsen Pty Ltd |
Primary insulin-like growth factor 1 deficiency |
Mar 2022 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Oesophageal carcinoma or HER-2-negative gastroesophageal junction adenocarcinoma |
Mar 2022 |
Deferred |
| TRIENTINE |
Waymade® |
Clinect Pty Ltd |
Wilson disease |
Mar 2022 |
Not Recommended |
| TEPOTINIB |
Tepmetko® |
Merck Healthcare Australia Pty Ltd |
Non-small cell lung cancer (NSCLC) |
Mar 2022 |
Recommended |
| LAROTRECTINIB |
Vitrakvi® |
Bayer Australia Ltd |
Solid tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions |
Mar 2022 |
Recommended |
| AVELUMAB |
Bavencio® |
Merck Healthcare Pty Ltd |
Urothelial carcinoma |
Mar 2022 |
Recommended |
| BECLOMETASONE WITH FORMOTEROL AND GLYCOPYRRONIUM |
Trimbow® |
Chiesi Australia Pty Ltd |
Asthma |
Mar 2022 |
Deferred |